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Abstract
Functional signaling between neural stem/progenitor cells (NSPCs) and brain endothelial cells (ECs) is essential to
the coordination of organized responses during initial embryonic development and also during tissue repair, which
occurs following brain injury. In this study, we investigated the molecular mechanisms underlying this functional
signaling, using primary mouse brain ECs and NSPCs from embryonic mouse brain. EC/NSPC co-culture
experiments have revealed that neural progenitors secrete factors supporting angiogenesis, which induce
noticeable changes in endothelial morphology. We demonstrate that NSPCs influence the expression of mTOR and
TGF-b signaling pathway components implicated in the regulation of angiogenesis. Endothelial morphogenesis, an
essential component of vascular development, is a complex process involving gene activation and the
upregulation of specific cell signaling pathways. Recently identified small molecules, called microRNAs (miRNAs),
regulate the expression of genes and proteins in many tissues, including brain and vasculature. We found that
NSPCs induced considerable changes in the expression of at least 24 miRNAs and 13 genes in ECs. Three NSPC-
regulated EC miRNAs were identified as the potential primary mediators of this NSPC/EC interaction. We found that
the specific inhibition, or overexpression, of miRNAs miR-155, miR-100, and miR-let-7i subsequently altered the
expression of major components of the mTOR, TGF-b and IGF-1R signaling pathways in ECs. Overexpression of
these miRNAs in ECs suppressed, while inhibition activated, the in vitro formation of capillary-like structures, a
process representative of EC morphogenesis. In addition, we demonstrate that inhibition of FGF, VEGF, and TGF-b
receptor signaling abolished NSPC-promoted changes in the endothelial miRNA profiles. Our findings demonstrate
that NSPCs induce changes in the miRNA expression of ECs, which are capable of activating angiogenesis by
modulating distinct cell signaling pathways.
Background
There is a close association and reciprocal signaling
that occurs between ECs and NSPCs in the neurogenic
zones of the adult brain. Recognition of this close rela-
tionship has led to the descriptive concept of a “neuro-
vascular niche”, where endothelial and neural cells
interact with each other, both prior to and throughout
their maturation. Cross-talk between the two cell types
is involved with differentiation, fate determination, and
migration of the NSPCs in vitro and in vivo, both in
the normal and injured brain [1-3]. In our previous
studies we demonstrated that NSPCs continuously
release a pro-angiogenic vascular endothelial growth
factor, VEGF, which promotes EC survival and mor-
phogenesis [4].
As an essential component of vascular development,
endothelial morphogenesis is a complex process invol-
ving gene activation and upregulation of specific cell sig-
naling pathways. Novel mechanisms regulating gene
expression were unveiled following the discovery of
microRNAs, which are single-stranded noncoding short
(18-24 nucleotides long) RNAs. It is now estimated that
up to one-third of encoded genes are regulated by miR-
NAs, which bind to their mRNA target at complemen-
tary sequences in order to downregulate gene
expression by inhibiting the mRNA translation into pro-
teins or by inducing mRNA degradation [5]. Recent
findings demonstrate that miRNAs control neurogenesis
[6,7] and could also help regulate the morphogenesis of
endothelial cells [8,9]. However, the role of miRNAs in
EC function currently remains unclear, and only a few
* Correspondence: troitbak@salud.unm.edu
1Department of Neurosugery, University of New Mexico Health Sciences
Center, Albuquerque, NM, USA
Full list of author information is available at the end of the article
Roitbak et al. Vascular Cell 2011, 3:25
http://www.vascularcell.com/content/3/1/25 VASCULAR CELL
© 2011 Roitbak et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.specific miRNAs targeting endothelial cell function and
angiogenesis have been identified. miRNAs including
the mir-let-7 family, as well as mir-21, mir-126, mir-
221, and mir-222 are highly expressed in endothelial
cells [9,10]. Studies have shown that Dicer and Drosha,
the RNase III endonucleases involved in miRNA genera-
tion, significantly affect angiogenesis [10,11]. Among
identified angiogenesis promoters is the miRNA cluster,
miR-17-92 [12]. miR-221 and miR-222 and miR-503
were also found to inhibit EC morphogenesis [8,13].
miR-155 has been found to be expressed in endothelial
cells and is implicated in the suppression of the angio-
tensin II receptor [14]. Recently, miR-100 was found to
regulate (inhibit) in vitro and in vivo vascularization, via
the mTOR signaling pathway [15]. The mammalian tar-
get of rapamycin (mTOR) is a protein kinase that regu-
lates the synthesis of numerous proteins, responsible for
modulating cell growth and behavior. The mTOR sig-
naling pathway is activated in response to the presence
of nutrients, growth factors, and hypoxia, resulting in
the phosphorylation of mTOR and the subsequent acti-
vation of numerous downstream targets [16,17].
Recently, mTOR phosphorylation by Akt protein kinase
was implicated as a trigger for cellular processes leading
to endothelial morphogenesis and angiogenesis [18,19].
The upstream regulator of mTOR activation, insulin-like
growth factor receptor (IGF-R) triggers mTOR phos-
phorylation via PI3K (phosphatidylinositol 3’kinase) and
Akt activation [17,20]. Together with mTOR, IGF-1R is
implicated in both the angiogenesis and metastasis for-
mation that occurs in cancer via expression of vascular
endothelial growth factor VEGF [21,22]. In turn, IGF-1R
and mTOR signaling are both modulated by miR-100
[23,24]. miRNA-155 is implicated in regulating expres-
sion of the transforming growth factor-b (TGF-b)a n d
its downstream target proteins, SMADs, which play a
crucial role in EC function and angiogenesis [25,26].
Methods
Cell Culture
Neural stem/progenitor cells (NSPCs) were established
from telencephalon of gestational day 14 mouse
embryos of the C57BL/6 strain mice (The Jackson
Laboratory)[4,27]. All animal procedures were approved
b yt h eU N MI n s t i t u t i o n a lA n i m a lC a r ea n dU s eC o m -
mittee (Animal Welfare Assurance # A3350-01; USDA
Registration # 85-R-0014). Briefly, embryonic telence-
phalons were dissected, and after removal of the
meninges, the tissue was mechanically dissociated by
tituration with a P-1000 pipetman in Hank’s balanced
salt solution (HBSS). After brief centrifugation (3 min,
1300 rpm), the cells were resuspended in culture med-
ium and plated into BIOCOAT 6-well poly-L-lysine
coated tissue culture dishes (Becton-Dickinson) at the
density of approximately one embryonic telencephalon
per well. NSPCs were expanded in defined serum-free
DMEM/F12 medium containing 15 mM HEPES, 2.5
mM L-glutamine (Gibco), 3 mM sodium bicarbonate, 25
μg/ml insulin, 16 μg/ml putrescine, 30 nM sodium sele-
nite, 100 μg/ml apo-transferrin, and 20 μM progesterone
(as previously described in [28]), plus 10 ng/ml EGF,
and 10 ng/ml bFGF (Invitrogen). The neural stem cells
from embryonic mice prepared by this method were
characterized earlier and fulfilled criteria of multipoten-
tiality and self-renewal [4].
Mouse brain endothelial primary cells (ECs) were
purchased from Celprogen (San Diego, CA). The cells
were grown in extracellular matrix (ECM) pre-coated
flasks, using Mouse Endothelial Complete Growth Med-
ium with Serum (both from Celprogen). According to
Celprogen Company recommendations, mouse forebrain
microvessels were isolated and maintained in the
endothelial medium, in T25 flasks pre-coated with
ECM. The micro-vessels ranged in diameter from 2 to
30 μm, from a single micro-vascular segment to a large
multi-branched plexus. ECs were isolated from the
micro-vessels via a mechanical dispersion and filtration
technique. Viability of the isolated cells was demon-
strated by good cell attachment/trypan blue dye exclu-
sion, and by prompt proliferation that resulted in
confluent cultures following 10 days. Confluent second-
ary cultures demonstrated the characteristic features of
endothelial cells. The ECs obtained were then character-
ized for the following marker profile: VEGFR2, CD309,
CD31, CD105, CD45, incorporation of acetylated Low
Density Lipoprotein (LDL), and CD147.
Indirect NSPC/EC co-culture using transwells
NSPCs were harvested by trypsinization, and plated onto
poly-L-lysine coated wells at a density of 1 × 10
5 cells
per well (9.5 cm
2 area per well of 6 well plate). NSPCs
were expanded in serum-free medium containing FGF
and EGF for 1 day. ECs were trypsinized and plated into
the upper compartment of BIOCOAT collagen I-coated
cell culture inserts (0.4 μm pore-size, Becton-Dickinson),
at a density of 2 × 10
4 cells per 4.2 cm
2 area and then
expanded in serum-containing EC medium for several
hours. The transwell co-culture system allows NSPCs
and ECs to share the same growth medium, and specifi-
cally allows substances to freely diffuse through cell cul-
ture inserts or cell strainer pores without allowing
physical contact between the two cell types [4]. NSPCs
and ECs were both rinsed with NSPC culture medium,
and the upper transwell compartments containing ECs
were placed into the culture well. Indirect NSPC/EC co-
cultures were maintained in growth factor-free and insu-
lin-free NSPC medium; 5% FBS was added into the co-
culture medium, in order to avoid the effect of serum
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our previous analysis, NSPCs remain undifferentiated
under these culture conditions for at least 2-3 days. For
CD31 immunostaining experiments, the ECs were
grown on the Matrigel matrix-coated coverslips and
placed in the upper compartments of the cell strainers
(74 μm nets) in the Corning netwell plates; NSPCs were
grown on the bottom of these plates.
Mouse angiogenesis antibody array
The composition of the angiogenesis modulators
secreted by NSPCs was examined using a Mouse angio-
genesis antibody array kit (Panomics), according to the
manufacturer’s recommendations. The array allows
simultaneous identification and quantification of
the expression of different angiogenesis regulators.
Angiogenesis array membranes were incubated with
pre-conditioned medium (concentrated 2-fold using a
Labconco-centivap concentrator) for 2 hours at RT. Pre-
c o n d i t i o n e dm e d i u mw a sc o l l e c t e df r o mN S P Ca n dE C
monocultures, grown for two days in serum-free and
growth factor-free NSPC and EC media, respectively.
The antibody array membranes were subsequently incu-
bated with biotin-labeled detection antibody mix. The
captured proteins were visualized using hemilumines-
cence detection of the streptavidin-HRP secondary
antibody.
Inhibitors for FGF, VEGF, and TGF-b pathways were
purchased from Millipore. The FGF/VEGF receptor tyr-
osine kinase inhibitor PD 173074 and a TGF RI kinase
inhibitor were used at 1 μMa n d1 0μMc o n c e n t r a t i o n s ,
respectively. EC/NSPC co-cultures were grown in the
presence of the inhibitors for 24, 48, and 72 hours.
Fresh inhibitors were added daily, and the viability of
the cells was monitored with the trypan blue dye exclu-
sion test.
Affymetrix microarray analysis
After 24 hours in transwell co-culture, the ECs and
NSPCs were separated and total RNA and miRNA were
isolated using RNeasy Mini Kit (Qiagen) and mirVana
miRNA (AB/Ambion) isolation kits, respectively. Flash-
PAGE fractionator (AB/Ambion) was used for rapid
PAGE-purification of miRNAs. Microarray analysis
using GeneChip Mouse 430 2.0 expression arrays and
GeneChip miRNA array chips (Affymetrix), was per-
formed in the Keck-UNM Genomic Resource Center. In
accordance to the MIAME guidelines, our microarray
raw data are deposited in the GEO NCBI database
http://www.ncbi.nlm.nih.gov/geo/, under accession num-
bers [GEO:GSE29759, GEO:GSE32352].
Total RNA preparation for gene expression analysis
The GeneChip
® 3’ IVT Express protocol (Affymetrix)
was used for RNA target preparation and for microarray
gene expression analysis, including a total RNA reverse
transcription, first-strand cDNA synthesis, and cDNA
conversion into a double-stranded DNA template for
transcription. The RNA was purified to remove unin-
corporated NTPs, salts, enzymes, and inorganic phos-
phate. Fragmentation of the biotin-labeled RNA
prepared the sample for hybridization onto GeneChip 3’
expression arrays. RNA purity and integrity was evalu-
ated for each sample, based on Agilent Bioanalyzer
Electropherograms.
miRNA labeling, hybridization, and scanning
Concentration of the isolated small RNAs was measured
on a Nanodrop spectrophotometer, and the size and
integrity of the purified miRNAs were determined using
an Agilent 2100 Bioanalyzer. The Genisphere FlashTag
HSR Labeling Kit (HSR10FTA) was used to label 100 ng
of miRNAs by performing a poly-A tailing reaction fol-
lowed by ligation of the biotinylated signal molecule to
the target RNA sample. After labeling, a small aliquot of
the RNA was used for an ELOSA QC assay to verify the
labeling efficiency, as recommended in the Genisphere
protocol. The biotin-labeled RNA sample was added to
the hybridization cocktail and incubated at 99°C for 5
minutes followed by 45°C for another 5 minutes before
being injected onto an Affymetrix miRNA Array. The
array was placed into a hybridization oven at 48°C for
16 hours. The microarrays were washed and scanned
using Affymetrix Fluidics and Scanning equipment.
MicroRNA normalization and analysis
We used the Affymetrix miRNA QC Tool to read in
and normalize the microarray measurements for each
RNA type. We used a robust microarray analysis (RMA)
normalization method, which consists of three steps:
background correction, quantile normalization (each
performed at the individual probe level), and robust lin-
ear model fit using log-transformed intensities (at the
probe set level). The average signal was determined for
the sample triplicates fore a c ho ft h e6 0 9m o u s em i R -
NAs on the Affymetrix arrays. Then the change in
miRNA expression was calculated between the controls
and the treated cells. A standard t-test was performed
and the p-values detected.
Gene expression analysis
Gene expression analysis was performed using two dif-
ferent summarization algorithms, MAS5 and RMA. The
transcripts in common between the two methods were
used to produce pathway networks for differential gene
expression. In both the MAS5 and RMA the same data
mining criteria were used to generate the transcript lists.
The Affymetrix raw data were imported into Gene-
Spring GX11.0.2 (Agilent Technologies). Then using the
Affymetrix MAS5 and the RMA algorithms, the 45101
transcripts on the Mouse 430 2.0 expression microarrays
were first filtered to remove any transcripts that were
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cifically, for each transcript, half of the samples had to
have a signal value above 100 or the transcript was
eliminated from further analysis. Next, the transcripts
that showed greater than a 2-fold change in expression
(either up- or downregulated) were retained. Finally, a t-
test with unpaired, unequal variance (Welch) with a p-
value < 0.05 was used to identify the statistically signifi-
cant transcripts. The resulting two lists of transcripts
from the two different summarization methods (MAS5
and RMA) were then compared using a Venn diagram,
and genes that were common to both methods were
reviewed.
Analysis of specific miRNA-associated signaling pathways
The final step in the miRNA analysis involved genera-
tion of pathway networks using the GeneGo software
(Thomson Reuters). Briefly, lists of genes and micro-
RNAs were uploaded to the GeneGo website where reg-
ulatory connections were created using statistically
significant altered genes and microRNA identified by
the GeneSpring data mining analysis. Using information
stored in current literature databases, regulatory dia-
g r a m sw e r ef o r m e dt oi l l u s t r a t et h ep o s s i b l et a r g e t sf o r
each miRNA.
Q-RT PCR
Q-RT PCR of the miRNA samples was performed using
a TaqMan MicroRNA reverse transcription kit and Taq-
Man microRNA assays (AB/Ambion) according to the
manufacturer’s recommendations. TaqMan
® Small RNA
assays are pre-formulated primer and probe sets
designed to detect and quan t i f ym a t u r em i R N A s .T h e
assays specific for mouse miR-155, miR-100, and miR-
let-7i, as well as the control snoRNA202 assay (Applied
Biosystems) were used based on the manufacturer’s pro-
tocols. Real-time PCR was performed on an ABI
7900HT fast RT-PCR system (Life Technologies, Carls-
bad, CA). The obtained raw data were analyzed using
the SDS2.4 and RQ Manager1.2.1 software that con-
verted the Ct values into fold-change values using the
snoRNA202 as the sample normalizing RNA.
EC transfection
Transfection was performed using a Lipofectamine -
2000-based technique, according to the manufacturer’s
recommendations (Invitrogen). Specific synthetic inhibi-
tors for miR-155, miR-100, and miR-let-7i, as well as
the Cy3 dye-labeled anti-miR control inhibitor (AB/
Ambion), were used in 30 nM concentration. For
miRNA overexpression experiments, we used miR-155,
miR-100, and miR-let-7i specific pre-miR miRNA pre-
cursors (mimics) and pre-miR miRNA negative control,
in a final concentration of 30 nM (AB/Ambion). EC sus-
pension was incorporated with the miRNA inhibitor/
mimic and transfection reagent (Lipofectamine) complex
and plated into the extracellular matrix pre-coated 12-
well cell culture dishes (Celprogen), at a density ~10 ×
5
cells/well. This early-stage transfection is very efficient,
since it occurs at an early period of cell adhesion, long
before ECs acquire the polarity characteristic of primary
cell cultures. Cells were transfected and plated in the
serum-free endothelial cell medium; then after 6 hours a
serum-containing EC medium was added to the cell cul-
tures (media was purchased from Celprogen). At 24
hours after transfection, the samples were subjected to
either Western blot analysis or in vitro EC morphogen-
esis/tube formation assay.
Endothelial cell morphogenesis assay
Endothelial cell tube formation was assessed using the
96-well format Angiogenesis Assay System (BD Bio-
Coat). This system is designed to enable rapid assess-
ment of angiogenesis modulating agents/molecules on
endothelial cell tube formation in a high-throughput
fashion. At 24 h after transfection with miRNA inhibi-
tors or mimics, 2 × 10
4 ECs were plated onto a Matrigel
matrix-pre-coated BD BioCoat Angiogenesis Plate,
according to the manufacturer’s recommendations. After
18-20 hours, the DIC images of unlabeled cells were
acquired using a Nikon TE2000 microscope and Slide-
Book software. In other experiments, tubular structures
were visualized using anti-GAPDH antibody, followed
by Rhodamin-conjugated secondary antibody. Rhoda-
min-labeled tubular structures were imaged using a
Zeiss LSM510 confocal microscope. 10 wells per
miRNA inhibitor/mimic were quantified, and 10 images
per well were acquired and analyzed. A number of para-
meters, such as tube length and branch points, were
used to evaluate tube formation. The counting and mea-
surements were performed using Image J software. Data
were subjected to Student’s t-test analysis using Graph-
Pad Prism software.
For quantification of CD31 membrane localization, the
ECs were plated on Matrigel matrix-pre-coated 12 mm
coverslips and placed in the upper compartment of the
cell strainers (74 μm nets) in the Corning netwell plates,
in co-culture with NSPCs. Control ECs were also placed
in similar inserts, but in the absence of NSPCs. 10
images per coverslip (6 coverslips per experiment, 3
independent experiments) were acquired with the 40×
objective on the Zeiss LSM510 confocal microscope,
and analyzed for CD 31 membrane expression, using
LSM Image Browser software.
Immunofluorescence Microscopy
Endothelial Cells and EC-formed tubular structures
were fixed with 4% paraformaldehyde solution and
quenched with 50 mM ammonium chloride. Following
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blocking with 1% horse serum, the samples were incu-
bated with the primary rat anti-mouse CD31 antibody
(Millipore, 1:100 in 1% donkey serum) or mouse
monoclonal anti-GAPDH (for 1 h at RT), followed by
incubation with FITC- and Rhodamine-conjugated sec-
ondary antibodies for 1 h, at RT, used at a 1:250 dilu-
tion (Jackson ImmunoResearch Laboratories). All
samples were imaged on a Zeiss LSM510 confocal ima-
ging system.
Western Blot analysis
Western Blot was performed as described previously [4].
The cells were scraped from cell culture dishes with 2 ×
SDS sample buffer (200 ml per well, 6 well plates), or
with lysis buffer (250 ml per well) containing 1% (vol/
vol) TX-100, 150 mM NaCl, 10 mM Tris-HCl pH 7.4,
and a protease inhibitor cocktail. Loading was confirmed
by comparing actin or GAPDH immunoreactivity across
the lanes. The proteins were separated on 4-20% gradi-
ent Criterion precast gels (Bio-Rad). A broad range
molecular weight calibration marker from 10,000 to
250,000 MW (Bio-Rad) was used as a standard. The
proteins were identified using, rabbit polyclonal anti-
SMAD 2 and 3 (1:500, Millipore), anti-actin (1:1000,
Sigma), mouse monoclonal anti-GAPDH (1:500, Milli-
pore), and rabbit polyclonal antibodies against IGF-1R
and p-53 (1:1000, Cell Signaling). Horseradish peroxi-
dase-labeled secondary antibodies from Amersham Bios-
ciences were used in dilution 1:3000. Incubation with
both primary and secondary antibodies was performed
for 1 h at room temperature. The expression and activ-
ity of the mTOR pathway components (including
mTOR, p-mTOR, and Raptor) were detected using
mTOR Pathway and mTOR Substates Antibody Sam-
pler Kits (Cell Signaling), according to the manufac-
turer’s recommendations. Experiments were performed
in triplicates. The density of the protein bands was
determined using AlphaEaseFC (Alpha Innotech) densi-
tometry software, normalized by actin or GAPDH
expression and quantified using GraphPad Prism
software.
Results
NSPCs support morphogenesis of the primary mouse
brain ECs
In our previously published studies we reported and
analyzed the significant influence of NSPCs on the mor-
phogenesis of ECs from the bEnd.3 cell line [4]. We
have observed an analogous phenomenon, using primary
mouse brain ECs in a special EC/NSPC co-culture sys-
tem (Methods). Changes in EC morphology and shape
were noticeable at 24 h, and became more prominent at
48 and 72 hours of co-culture with NSPCs. The ECs in
co-culture assembled into tubule-like structures, which
normally only occurs upon initiation of in vitro morpho-
genesis (Figure 1B). We performed immunofluorescence
analysis of the cellular localization of the EC marker
protein CD31 (PECAM-1, Platelet Endothelial Cell
Adhesion Molecule-1). Together with VE-cadherin,
CD31 functions as a cell-cell adhesion and signaling
molecule, regulating EC differentiation and morphogen-
esis [29]. Under the usual growing conditions (on cell
culture filters or coverslips), this protein was rarely
expressed in EC membranes. To induce differentiation
and morphogenesis, ECs were plated on Matrigel matrix
and allowed to differentiate for 24 hours, in the pre-
sence (Figure 1D) or absence (Figure 1C) of NSPCs.
CD31 was localized to the cell membranes in approxi-
mately 56% of the ECs co-cultured with NSPCs (Figure
1D, arrowheads and insert), in contrast to the mostly
intracellular localization seen in EC monocultures
(Figure 1C, insert). These results suggest that NSPCs
support both morphogenesis and differentiation of ECs.
NSPCs constitutively release angiogenesis activators
We have previously demonstrated that NSPCs constitu-
tively express and release a pro-angiogenic factor, VEGF
Figure 1 NSPCs support morphogenesis and differentiation of
primary mouse brain ECs. ECs were grown alone (A) or in co-
culture with NSPCs (B) for 48 hours. The cells were visualized by
IF staining for actin, using acti-stain 488 fluorescent phalloidin (red,
pseudo-color), and DAPI nuclear stain (blue). Bar 20 μm. Note the
changes in NSPC-induced EC morphology, also demonstrated on
the high magnification images (inserts). C and D: immunostaining
with CD31 antibody (the cells were plated on Matrigel matrix).
CD31 (green) was localized to the cell membrane of the ECs
co-cultured with NSPCs (D, arrowheads and insert), in contrast to its
intracellular localization in EC monocultures (C). Bar 10 μm.
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detailed analysis of the pre-conditioned medium col-
lected from the NSPC cultures, using a Mouse Angio-
genesis Antibody Array Kit (Panomics). Analysis of the
pre-conditioned media collected after 24 hours in cul-
ture, detected that, besides VEGF, these NSPCs were
able to release a number of other identifiable pro-angio-
genic factors, including tumor necrosis factor (TNF-a),
transforming growth factor (TGF-b), epidermal growth
factor (EGF), and fibroblast growth factor (FGF-a).
Among these released angiogenesis activators, we also
detected cytokines, including the interleukins IL-1a and
IL-1b and the protein hormone leptin (Figure 2A). Ana-
lysis of the pre-conditioned medium collected from EC
cultures only detected the cytokine IL-6 (Additional file
1A). The lack of the VEGF and other factors normally
secreted by EC cultures could be attributed to serum
starvation (the assay requires serum-free conditions),
and thus was able to serve as an assay validation control.
Taken together, our previously published and present
results demonstrate the strongly pro-angiogenic proper-
ties of NSPCs.
Co-culture with NSPCs induces upregulation of the mTOR
and TGF-b signaling pathway components in ECs
We aimed to establish a link between the NSPC-induced
changes in EC morphology and the major signaling
pathways responsible for regulating EC differentiation
and morphogenesis. We performed a Western blot ana-
lysis of ECs grown in co-culture with NSPCs, using an
mTOR signaling pathway antibody kit and the antibo-
dies against the major components of TGF-b signaling,
and the proteins SMAD-2 and SMAD-3. Co-culture
with NSPCs for 24 hours induced a significant increase
in the expression of major components of mTOR signal-
ing, as compared to EC monoculture: Rictor was notice-
ably increased, mTOR protein expression was increased
2.4 times and Raptor increased ~ 4-fold. Expression of
the proteins SMAD-2 and SMAD-3 was increased ~ 1.6
and ~ 1.8-fold, respectively (Figure 2B). These results
demonstrate that NSPCs significantly affect the expres-
sion of signaling proteins regulating critical cellular pro-
cesses in ECs.
NSPCs influence miRNA expression in ECs
Next, we investigated whether the NSPC-induced altera-
tions in EC morphology, and changes in the expression
of signaling molecules, were also associated with
changes in the miRNA profiles of ECs. miRNA expres-
sion levels were evaluated in ECs and NSPCs grown in
mono- or co-cultures for 24 hours. The profiling was
based on Affymetrix microarray analysis using miRNA
array chips (Affymetrix). Expression of 24 miRNAs was
a l t e r e db ym o r et h a n2 - f o l di nt h eE C sw h i c hw e r e
grown in the presence of NSPCs, as compared to EC
monocultures. Within the group, 7 miRNAs were
Figure 2 NSPCs constitutively release angiogenesis activators and induce upregulation of the mTOR and TGF-b signaling pathway
components in ECs. A: Pre-conditioned medium collected from the NSPCs cultured for 24 hours, was analyzed using a Mouse Angiogenesis
Antibody Array Kit. The array membrane with the immobilized specific antibodies against different pro-angiogenic factors, was incubated with
the pre-conditioned medium. The bound proteins were visualized with secondary detection antibody followed by chemiluminescence detection.
B, graph: ECs were grown as monoculture (clear bars) or were co-cultured with NSPCs (black bars). After 24 hours in culture, the cell lysates were
subjected to Western blot. Immunoblot analysis was performed using the antibodies against mTOR, Rictor, Raptor, SMAD-2/SMAD-3, and actin.
Signal intensities were quantified with AlphaEaseFC densitometry software. Relative density was calculated by the ratio of the protein of interest
vs actin band intensities, and displayed graphically. Values represent the mean ± S.E.M. (n = 3, p < 0.05, Student’s t-test). Immunoblot on the
right depicts the representative experiment. Lane 1: ECs grown as a monoculture; lane 2 - ECs grown in co-culture with NSPCs.
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(Figure 3A). Reciprocally, co-culture with ECs resulted
in the upregulation of miR-210, miR-685, miR-129-5,
and the downregulation of miR-124 in the co-cultured
NSPCs (Figure 3B).
NSPCs also altered the expression (mostly upregu-
lated) of 13 genes in ECs. The analysis revealed that the
presence of NSPCs considerably alters gene expression
in ECs. Among those that were upregulated are genes
encoding: fibromodulin (4.4-fold) mediating TGF-b sig-
naling, insulin-like growth factors IGF-1 and IGF-2 (>
2-fold), which are implicated in EC morphogenesis, and
the angiogenesis promoters periostin and von
Willebrand factor (Additional file 1B, red). These results
once more demonstrate the pro-angiogenic properties of
NSPCs.
MicroRNAs miR-155, miR-100, and miR-let-7i
MicroRNAs miR-155, miR-100, and miR-let-7i, which
are downregulated in ECs under the influence of
NSPCs, were identified as potential mediators of the
NSPC/EC interaction. Our choice was based on reports
in the current literature, as well as on the information
gathered from the MetaCore pathway analysis software,
which indicated that components of the NSPC-affected
signaling pathways in ECs, can be also influenced
Figure 3 NSPCs alter the miRNA profile in ECs. miRNA profiling of the ECs and NSPCs co-cultured for 24 hours was performed using
Affymetrix microarray analysis with miRNA array chips. A: Seven miRNAs were upregulated (red) and seventeen downregulated (blue) in the ECs
co-cultured with NSPCs. B: Reciprocally, co-culture with ECs resulted in the upregulation of three (red) and downregulation of one (blue) miRNAs
in the NSPCs. C: The pathway networks were generated using MetaCore pathway analysis and data mining algorithms from the GeneGo
software. Arrows indicate the association and interactions between components of the miRNAs and their known target molecule networks.
Green arrows indicate positive, red arrows are negative, and grey arrows designate an unspecified effect.
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est. According to the literature, miR-100 regulates
mTOR signaling [23], miR-155 regulates SMAD protein
expression [25], and miR-let-7i is a member of a larger
angiogenesis regulating miRNA family [30]. MetaCore
pathway analysis and data mining algorithms from the
GeneGo software determined that the major negatively
regulated factors influenced by miR-155 and miR-100,
include mTOR, Raptor, and SMAD proteins (Figure
3C). The upregulation of mTOR, Raptor, and SMADs in
ECs co-cultured with NSPCs was accompanied by
downregulation of miR-155, miR-100, and miR-let-7i,
which points to the possible involvement of these miR-
NAs in mediating NSPCs influence on EC morphology
and protein expression. Affymetrix analysis data for the
three miRNAs were validated by Q-RT PCR using speci-
fic miRNA primer sets. Q-RT PCR analysis detected a 6-
fold downregulation of miR-155, a 3-fold downregula-
tion of miR-100, and a 2.8-fold downregulation of miR-
let-7i, in the ECs grown in the presence of NSPCs (as
compared to EC monocultures). Thus, changes seen in
the expression of miR-155, miR-100, and miR-let-7i are
consistent between the two methods: all three miRNAs
were suppressed in ECs grown in the presence of
NSPCs.
Specific miRNA inhibitors and mimics alter the protein
expression in ECs
For the miRNA functional studies, we first performed
transfection of ECs with synthetic inhibitors for the spe-
cific miRNAs miR-155, miR-100, and miR-let-7i (30 nM
final concentration). Cy™3 dye-labeled anti-miR™ was
used as a negative control. For miRNA overexpression,
miR-155, miR-100, and miR-let-7i-specific pre-miR
miRNA precursors, and the pre-miR miRNA negative
control were transfected into ECs. Cells were transfected
using a Lipofectamine-2000-based transfection techni-
que. Incorporation of Cy™3 dye assessed 24 hours later
demonstrated ~ 80-90% transfection efficiency (Addi-
tional file 2A-D). miRNA expression levels were deter-
mined 24 hours post-transfection with Q-RT-PCR,
demonstrating that the use of anti-miRs and pre-miRs
resulted in a very strong miRNA inhibition and overex-
pression, respectively (Additional file 2E and 2F). 24
hours after transfection, EC lysates were subjected to
immunoblot analysis using the mTOR signaling pathway
antibody kit and antibodies recognizing SMAD-2 and
SMAD-3. The changes in protein expression levels
influenced by the inhibition of miR-100, miR-155, and
miR-let-7i, were quantified (based on the results of at
least three independent experiments). The fold changes
in protein expression, as compared to the control sam-
ples, are plotted on the graph on Figure 4A. Figure 4B
demonstrates the appearance of western blots from the
representative experiment. Transfection of anti-miR-155
into the ECs resulted in activation of the mTOR path-
way, identified by a significantly increased expression
and phosphorylation of mTOR, as well as upregulation
of the Raptor protein. Inhibition of miR-155 also
resulted in a highly increased expression of SMAD-2
protein. Inhibition of miR-100 and miR-let-7i resulted
in the upregulation of SMAD-2 and SMAD-3
(Figure 4A and 4B). Thus, a decreased expression of
miRNAs 155, 100, and let-7i in ECs induced the upregu-
lation of major components of the mTOR and TGF-b
signaling pathways.
Overexpression of miR-100 resulted in a significant
(more than 35%) decrease in mTOR phosphorylation
(Figure 4C and 4D, p-mTOR). These findings are in
agreement with other studies demonstrating a negative
effect of miR-100 on IGF-1R and mTOR signaling path-
ways [23]. The levels of expression of SMAD proteins
were not affected by the pre-miRNA transfection (data
not shown). We therefore checked whether the specific
pre-miRNAs affected expression of the other possible
target proteins. According to TargetScan miRNA target
prediction software, the insulin-like growth factor recep-
tor IGF-1R is a possible predicted target for miR-100
and the miR-let-7 cluster. In agreement with this predic-
tion, overexpression of miR-100 and miR-let-7i leads to
significant downregulation (43 and 34%, respectively) of
both precursor (pro-IGF-1R) and mature forms of IGF-
1R. Downregulation of both mTOR phosphorylation and
IGF-1R expression in the analyzed cell lysates, was
accompanied by the upregulation of their negative regu-
lator protein, p53 (Figure 4C and 4D). We speculate
that miR-100 upregulation suppresses mTOR phosphor-
ylation (and thus mTOR signaling) via a p53/IGF-1R/
mTOR signaling pathway. Interestingly, co-expression of
miR-155 and miR-100 resulted in a dramatic (~67%)
reduction of mTOR phosphorylation (Figure 4C, striped
bar and D, right immunoblot), suggesting a possible
synergistic action of these two miRNAs in the regulation
of mTOR activity.
Overall, the experiments involving miRNAs 155, 100,
and let-7i inhibition and overexpression, demonstrate
that these miRNAs affect mTOR, TGF-b and IGF-1 sig-
naling pathway components, which are implicated in
regulating EC morphogenesis and angiogenesis.
Changes in miR-155, miR-100 and miR-let-7i expression
significantly affect in vitro endothelial morphogenesis
We investigated the effect of EC miRNA inhibition and
overexpression on in vitro endothelial morphogenesis
(the ability of ECs to form the capillary-like tubules
when plated on Matrigel matrix or collagen). This in
vitro model of angiogenesis is commonly used to per-
form EC functional studies. ECs were transfected with
Roitbak et al. Vascular Cell 2011, 3:25
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miR-let-7i, and Cy3 dye-labeled anti-miR control inhibi-
tor. To study the effect of miRNA overexpression, ECs
were transfected with miR-155, miR-100, and miR-let-
7i-specific pre-miR miRNA precursors and pre-miR
miRNA negative control. At 24 hours after transfection,
the cells were harvested and subjected to in vitro EC
morphogenesis assay (Methods). Analysis was performed
at 18-20 hours after plating on Matrigel matrix. The in
vitro endothelial morphogenesis assay demonstrated that
Figure 4 Altered expression of specific miRNAs in ECs effect expression of signaling proteins. A and B: Inhibition of miRNAs 155, 100, and
let-7i in ECs induce the upregulation of components of the mTOR and TGF-b signaling pathways. ECs were transfected with synthetic inhibitors
for miR-155, miR-100, and miR-let-7i, as well as Cy3 dye-labeled control anti-miR. At 24 hours post-transfection, EC lysates were subjected to
immunoblot analysis using an mTOR signaling pathway antibody kit and antibodies against SMAD-2/SMAD-3, actin, and GAPDH. Protein
expression was normalized by GAPDH expression and quantified using the GraphPad Prism software. A: Protein expression fold changes (anti-
miR-transfected vs control anti-miR-transfected cells) are displayed graphically. B: Representative immunoblots for the data depicted on A. C and
D: miRNA overexpression experiments. ECs were transfected with pre-miR miRNA negative control, miR-155, miR-100, and miR-let-7i-specific pre-
miR miRNA precursors, or co-transfected with pre-miR-155 and pre-miR-100 (pre-miR-155+100). At 24 hours post-transfection, the cell lysates
were immunoblotted with the antibodies against phospho-mTOR, IGF-1R (recognizing both pro- and mature form of the receptor), p53, and
GAPDH (loading control). Protein expression was normalized by GAPDH expression and quantified using the GraphPad Prism software. C: Protein
expression fold changes (pre-miR-transfected vs control pre-miR-transfected cells) are displayed graphically. Values represent the mean ± S.E.M.
(n = 3, p < 0.05, Student’s t-test). D: Representative immunoblots for the data depicted on C.
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Page 9 of 15inhibition of miR-155, miR-100 and miR-let-7i signifi-
cantly enhanced EC morphogenesis: the number of
tubule branch points (thus complexity of the tubular
structures) was significantly increased. Another charac-
teristic parameter, tubule length, was also significantly
increased after the inhibition of miR-155 and miR-100
(Figure 5A). In contrast, overexpression of all three miR-
NAs resulted in significant suppression of the in vitro
tube formation (Figure 5B).
Overall we conclude that NSPCs support EC morpho-
genesis and differentiation via specific microRNAs.
NSPC-regulated miR-155, miR-100, and miR-let-7i alter
in vitro EC morphogenesis, possibly through modulation
of pro-angiogenic mTOR, TFG-b and IGF signaling
pathways.
Inhibition of FGF, VEGF, and TGF receptors suppress
NSPC-induced changes in endothelial miRNA profiles
In our previous studies we reported that the EC-sup-
porting effects of NSPCs are inhibited by the VEGFR2
tyrosine kinase inhibitor SU1498, as well as by Flt-1-Fc,
which acts as a decoy receptor to inhibit VEGF signaling
[4]. In the experiments described below, we aimed to
establish a possible functional link between the NSPC-
released pro-angiogenic factors including FGF, VEGF,
and TGF and the decreased expression of miRNAs
155, 100, and let-7i in ECs. We checked whether the
inhibition of the FGF, VEGF, and TGF signaling path-
ways would influence the miRNA profile in ECs, which
have been co-cultured with NSPCs. In these experi-
ments, ECs were co-cultured with NSPCs using a
transwell co-culture system. The cell co-cultures were
incubated in a medium containing the FGF/VEGF
receptor tyrosine kinase inhibitor PD 173074 (1 μMi n
DMSO, Millipore), and the TGF-b kinase inhibitor
SB431542 (10 μM in DMSO, Millipore). Control ECs
grown on the transwell inserts, but in the absence of
NSPCs, were incubated with the same volume of
DMSO. According to the manufacturer, PD 173074 is
a highly specific inhibitor of FGF and VEGF receptors,
which has been shown to inhibit FGF- and VEGF-
induced angiogenesis. SB431542 has been shown to
effectively inhibit the TGF-b signaling cascade and
phosphorylation (activation) of SMAD-2. These inhibi-
tors did not affect the proliferation rate of the ECs, as
their number had doubled during the 48-hour incuba-
tion with PD 173074 and SB431542. Viability of the
NSPCs in co-culture was not reduced by the inhibitor
treatment, which was verified using the trypan blue
dye exclusion test.
Affymetrix analysis of the ECs treated with PD 173074
and SB431542 for 24 hours, showed that the inhibitors
eliminated the NSPC effect on the endothelial miRNA
profile, as demonstrated earlier in the table seen in
F i g u r e3 .I nt h ep r e s e n c eo fP D1 7 3 0 7 4 ,t h ee x p r e s s i o n
of miR-155, miR-100, and miR-let-7i in ECs did not
change after 24 hours of co-culture with NSPCs (the
fold change of the miRNA expression was +1.02, -1.07,
and -1.02, respectively). Similarly, SB431542 also elimi-
nated NSPC-induced miRNA expression changes:
miRNA-155 decreased by 1.15-fold, miR-100 increased
1.16 fold, and the miR-let-7i fold change was 1.05. As
shown in Figures 6A and 6B, treatment with these inhi-
bitors impaired the expression of other miRNAs. Inter-
estingly, according to the information from TargetScan,
one of the upregulated miRNAs, miR-690 (Figure 6A), is
a negative regulator of the mTOR signaling pathway
component Rictor, as well as of the insulin-like growth
factor receptor IgF2-R. Mir-210, which is downregulated
in ECs under the influence of both PD 173074 and
SB431542 (Figure 6A and 6B), is known to have a pro-
angiogenic function [9].
As described above, NSPCs induce activation of
mTOR and TGF-b signaling pathways in ECs. Accord-
ingly, co-culture with NSPCs for 24 hours resulted in
strong phosphorylation of m-TOR in ECs (Figure 6C).
Following inhibition of FGF/VEGF receptors for 24
hours, the NSPC-induced mTOR phosphorylation was
significantly decreased, as compared with control ECs
co-cultured with NSPCs (and treated with DMSO only):
PD 173074 induced a 49% and SB431542 induced a
~35% decrease in mTOR phosphorylation levels (Figure
6C). These results demonstrate that signal transduction
between NSPCs and ECs, resulting in activation of the
mTOR pathway in ECs, could be mediated via FGF/
VEGF and TGF-b receptor signaling.
Discussion
In our previous studies on NSPC-induced EC morpho-
genesis, we primarily focused on the molecules and sig-
naling pathways effected in NSPCs. In the present study,
we were interested in the molecular alterations occur-
ring in ECs, induced under the influence of NSPCs. The
significant changes in EC morphology observed in our
present study, were not initiated by either the growth
medium or supporting substrate, but rather were influ-
enced by the diffusible factors released by NSPCs in our
segregated co-culture system.
Gene and miRNA profiling analysis supported our
visual observations: NSPCs induced more than 2-fold
upregulation of seven, and downregulation of seventeen,
endothelial miRNAs. Among the downregulated miR-
NAs, miRNA-503 and miR-31 were recently found to
impair EC function, as well as restorative angiogenesis
processes [13,31]. These recent findings were very
encouraging for us, and are in agreement with our own
results. However, many of the identified miRNAs are
not apparently implicated in the regulation of in vitro
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Page 10 of 15Figure 5 Changes in miR-155, miR-100, and miR-let-7i expression affect in vitro endothelial morphogenesis. 24 hours after transfection
with specific synthetic inhibitors (A) or mimics (B), ECs were subjected to in vitro EC morphogenesis assay. DIC images of unlabeled cells were
acquired using a Nikon TE2000 microscope and SlideBook software (DIC micrographs). GAPDH-labeled low-magnification images of the tubular
structures (red, inserts) were acquired using a Zeiss LSM confocal microscope. Bars 20 μm. Graphs: Data are expressed as the average tube
length, or number of branch points per visual area ± S.E.M., n = 10 wells per inhibitor/10 images per well. Student’s t-test: * P < 0.05; **P < 0.01;
*** P < 0.001.
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Page 11 of 15Figure 6 Inhibition of FGF, VEGF, and TGF receptors suppress NSPC-induced changes in ECs. A and B: miRNA profiling (using Affymetrix
microarray analysis) of the ECs co-cultured with NSPCs for 24 hours, in the presence of 1 μM FGF/VEGF receptor tyrosine kinase inhibitor (A) and
10 μM TGF-b kinase inhibitor (B). In control samples, the miRNAs were isolated from ECs grown on the transwell inserts as monocultures (in the
absence of NSPCs), and treated with the same volume of the vehicle (DMSO). Significantly (~ 2 fold) upregulated miRNAs in the inhibitor-treated
ECs from EC/NSPC co-cultures, as compared to control samples are shown in red, downregulated miRNAs are depicted in blue. C: Cell lysates
were prepared from: ECs grown on cell culture filters alone, 2 μl/mL DMSO was added to the medium (clear bar on the graph and lane 1 on
the representative immunoblot); ECs grown in co-culture with NSPCs, 2 μl/mL DMSO was added to the medium (black bar on the graph and
lane 2 on the immunoblot); ECs grown in the presence of NSPCs, medium containing 1 μM FGF/VEGF receptor tyrosine kinase inhibitor PD
173074 (grey bar on the graph and lane 3 on the immunoblot); ECs grown in the presence of NSPCs; medium containing 10 μM TGF-b kinase
inhibitor (striped bar on the graph and lane 4 on the immunoblot). Immunoblots were probed with anti-phospho-mTOR antibody. Signal
intensities were quantified with AlphaEaseFC densitometry software. Relative density was calculated by the ratio of the protein of interest vs
actin band intensities, and displayed graphically. Values represent the mean ± S.E.M. (n = 3, p < 0.05, Student’s t-test).
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that, unlike other studies, we identified miRNAs specifi-
cally influenced by the pro-angiogenic effect of NSPCs.
The functional studies of the changes involved with
NSPC-induced pro-angiogenic gene expression will be a
subject of our future investigations.
In our search for the potential mediators of this
NSPC/EC interaction, we focused on the miRNAs
responsible for regulating the components of TGF-b
and mTOR signaling pathways, since these pathways
were influenced by NSPCs in our co-culture experi-
ments. Our functional studies, including miRNA overex-
pression and inhibition in ECs, in combination with
endothelial tube formation assays, confirmed the validity
of our miRNA choices. Of these choices miR-100 and
miR-155 demonstrated the most prominent effects on
EC morphogenesis.
In the present study, we did not aim to identify or
confirm the genuine target genes for miR-155, miR-100,
and miR-let-7i. A thorough investigation of these tar-
gets, requiring complex miRNA target screening strate-
g i e s ,i sb e y o n dt h es c o p eo ft h i sa r t i c l e .I n s t e a d ,w ea r e
interested in the miRNA regulation of cell signaling
pathways, focusing on miRNA/signaling protein net-
works more than on the individual interactions between
miRNAs and their predicted targets. Our miRNA inhibi-
tion and overexpression experiments demonstrate a
clearly negative effect from the three miRNAs on the
mTOR and TGF-b pathway components. However, we
propose that the proteins influenced by these three miR-
NAs of interest may represent their secondary, rather
than direct targets. This explains our findings, indicating
that different signaling pathways are affected by inhibi-
tion and overexpression of the same miRNAs, which
points to the complexity of these alterations in the gene
regulatory system. It is possible that changes in miRNA
levels result in the exclusion, or addition, of intermedi-
ate targets/miRNAs within the signaling circuitry, and
are able to activate different cell signaling pathways. The
miRNA functional synergistic networks, where multiple
miRNAs control individual genes, were described earlier
[32]. Our miR-155 and miR-100 double-overexpression
results point to a possible synergistic negative action of
these two miRNAs.
In our earlier studies we showed that there are pro-
angiogenic functions of the NSPCs, which are mediated
through HIF-1a-triggered sustained release of VEGF
[4,27]. In the present study we identified additional
angiogenesis modulators that are produced and released
by NSPCs. These modulators include TNF-a,T G F - b,
EGF, FGF-a, interleukins IL-1a and IL-1b and a highly
expressed protein hormone leptin. Leptin has been
recently implicated in the regulation of angiogenesis
and fetal brain development. Notably, the highest
concentrations of leptin are detected in fetal mouse
between embryonic days E14-E18, at the peak of the
embryonic neurogenesis [33]. Our experiments using
inhibitors of FGF/VEGF and TGF-b receptors demon-
strate that NSPCs affect ECs via pro-angiogenic fac-
tors and that FGF and/or VEGF receptors mediate the
NSPC-induced changes in EC miRNA profiles. The
interpretation of our results, as well as our hypothesis
on the possible mechanisms of signal transduction
between NSPCs and ECs, involving NSPC-released
pro-angiogenic factors, miRNA expression, and regu-
lation of the signaling pathways mediating EC mor-
phogenesis, is illustrated in Figure 7. Panel A
represents a possible general scheme of NSPC-sup-
ported EC morphogenesis: NSPC-released pro-angio-
genic factors induce changes in miRNA and gene
expression in ECs, leading to activation of cell signal-
ing pathways regulating EC morphogenesis. Panel B
summarizes our findings and illustrates a possible
link between NSPC signaling, alterations in EC
miRNA expression, and the process of endothelial
morphogenesis. We speculate that NSPC-released
pro-angiogenic factors, bind to the corresponding
receptors on EC surfaces and trigger activation of the
transcriptional or post-transcriptional suppressors of
miRNAs 155, 100, and let-7i. Resulting downregula-
tion of miR-155 leads to the increased expression of
mTOR, SMAD2, and SMAD3, and thus activation of
the mTOR and TGF-b signaling cascade and tran-
scription of genes responsible for endothelial morpho-
genesis. It is not known whether or not the
transcriptional and/or post-transcriptional regulators
of miR-155 (such as ETS1), miR-100, and miR-let-7i
(including MYC and LIN28) are affected by NSPCs
and pro-angiogenic receptor signaling. This will be a
subject of our future investigations.
Co-culture with ECs induced reciprocal changes, both
in gene and miRNA profiles in the NSPCs, as well.
MiR-210 expression was significantly increased (more
than 3-fold) in NSPCs co-cultured with ECs. This
miRNA is upregulated by hypoxia inducible factors, the
HIF-proteins, resulting in VEGF-mediated angiogenesis
[34]. According to our unpublished studies, the presence
of ECs induces the activation HIF-1a/VEGF signaling in
NSPCs. Thus, our miRNA profiling results establish a
link between miRNA-210 and HIF-1a/VEGF signaling
in NSPCs. A more detailed analysis of the reciprocal
changes in gene and miRNA expression found in the
NSPCs will be another subject of our further
investigations.
In summary, we have identified a number of genes
and miRNAs that are impaired in ECs which are under
the influence of NSPCs. Based on the significant effects
of NSPCs on EC morphology and behavior, the
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transcriptional and post-transcriptional regulation of EC
morphogenesis. An effective cross-talk between NSPCs
and ECs is a requirement for the highly coupled pro-
cesses of neurogenesis and vasculogenesis, and are criti-
cal for healing and neurorestoration after a brain injury.
Therefore investigation of the molecules involved in this
NSPC/EC interaction could lead directly to the develop-
ment of novel strategies for regulating neurorestorative
processes.
Additional material
Additional file 1: Analysis of the EC-pre-conditioned medium.E C
gene profile changes following co-culture with NSPCs. A: Pre-conditioned
medium collected from the ECs, cultured for 24 hours, was analyzed
using a Mouse Angiogenesis Antibody Array Kit. B: Co-culture with NSPCs
results in altered (mostly upregulated) gene expression in ECs. Gene
profiles were evaluated in ECs and NSPCs grown in mono- or co-cultures
for 24 hours, using mouse genome array chips and analyzed using
GeneSpring GX11.0.2 software. Significance of the changes was verified
via the Affymetrix MAS5 and the RMA algorithms. 13 gene transcripts,
common to both the MAS5 and the RMA analyses according to our
Venn diagram, where identified as significantly altered in ECs under the
influence of NSPCs. 10 genes with significantly increased (red) and 3
genes with significantly decreased (blue) expression were detected.
Additional file 2: Efficiency of EC transfection with specific miRNA
inhibitors and precursors. DIC (A) and immunofluorescence (B),
immunostaining with anti-CD31 (green), confocal images of the ECs
transfected with Cy-3-conjugated control miRNA inhibitor, depicted in
red (24 hours post-transfection). C and D: Transfected ECs were plated
onto Matrigel matrix for 24 hours and subjected to immunofluorescence
staining with anti-CD31 antibody (green). Orthogonal image projection
demonstrates the intracellular localization of the Cy-3-conjugated control
(red). Bars: 20 μmo nB ;1 0μm on C. E and F: Efficiency of the miRNA
inhibition and overexpression. ECs were transfected with pre-miR miRNA
precursors (E) and anti-miR inhibitors (F) specific for miR155 and miR-100.
At 24 hours after transfection, Q-RT PCR was performed using TaqMan
preformulated primer sets specific for these miRNAs. The obtained raw
data were analyzed using the SDS2.4 and RQ Manager1.2.1 software that
converted the Ct values into fold-change values using the snoRNA202 as
the sample normalizing RNA. miRNA expression fold changes (specific
anti/pre-miR-transfected vs control anti/pre-miR-transfected cells) are
displayed graphically.
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